Medilytix Bureau:

Hyderabad-based Indian Immunologicals Ltd (IIL) has started supplying basic drug raw material to Bharat Biotech International Limited (BBIL) to produce more doses of the indigenously developed Covaxin. The development is significant since the country is trying to augment Covid-19 vaccine production capacity to meet its vaccination target.

India currently gets about 2 crore doses of Covaxin and 10 crore doses of Covishield from the Pune-based Serum Institute of India. Covaxin supplies were projected to increase to around 2.5 crore doses in August. Additionally, 2 million doses of Covaxin are expected to be delivered between August and September. The Covishield production, too, is expected to increase by another 2 crore vaccine doses.

The Central government had directed the IIL and Bharat Biotech to join hands in April, as Bharat Biotech was struggling to augment its capacity. IIL also received a grant of Rs 60 crore towards enhancing production capabilities. IIL was set up by the National Dairy Development Board (NDDB) in 1982.

IIL said in a short time, it has performed several activities, including the signing of four agreements with Bharat Biotech, repurposing its manufacturing facility in Hyderabad, procurement of key raw materials and consumables, procurement of key equipment for the process, technology transfer, trials at R&D scale, and training.

Leave a Reply

Your email address will not be published. Required fields are marked *